Twenty-five million Americans suffer from ulcers. An ulcer is a sore or hole in the lining of the stomach or duodenum (the first part of the small intestine). People of any age can get an ulcer and women are affected just as often as men.
Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that nine out of ten ulcers are caused by H. pylori. Medicines that reduce stomach acid may make you feel better, but your ulcer may come back. Here's the good news: Since most ulcers are caused by this bacterial infection, they can be cured with the right antibiotics.
People suffering from diabetes-related foot ulcers show different rates of healing according to the way they cope and their psychological state of mind, according to new research by a health psychologist at The University of Nottingham.
In a new article in the journal Australian Prescriber, there is a warning that combination painkillers cause more side effects and may not provide the relief promised. This comes from the National Prescribing Service (NPS), Australia's medicine review body.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.
More than one billion people all over the world suffer from tropical diseases which are mostly unknown to the wider public and have also been neglected economically. In a joint effort with four other European foundations, the Volkswagen Foundation has opened a second round of funding for African scientists conducting research on these neglected diseases.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
Wellstar through its wholly owned subsidiary Trillennium Medical Imaging (TMI) announces the Delivery of 2 Prototypes of the TMI Clinical Camera Design.
Pfizer Inc., together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 from two podium and four poster presentations.
Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™: Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.
Cumberland Pharmaceuticals Inc. today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene. The study, which is the first to document an antipyretic effect of an injectable non-steroidal anti-inflammatory drug on fever caused by malaria, demonstrated that patients who received intravenous ibuprofen experienced a greater reduction in their temperatures than those who received placebo.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces the achievement of regulatory and commercial milestones.
Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Zeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract.
Researchers have identified cells in the immune system that react to the stomach ulcer bacterium Helicobacter pylori, one of the risk factors for the development of stomach cancer. This discovery could lead to faster diagnosis and treatment as well as a better prognosis for patients with stomach cancer, reveals a thesis from the University of Gothenburg, Sweden.
Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.
EarlySense announced today that its EverOn Touch system has been cleared for marketing by the U.S. Food and Drug Administration. The FDA clearance covers several key additions to the traditional EverOn contact-free patient supervision system value proposition. For the first time, the EverOn system includes an online display that alerts medical staff regarding a patient's motion level and verifies patient turns as indicated by nurses. Identifying low patient movement and then turning patients methodically are key elements in the prevention of pressure ulcers, the most costly patient safety risk in U.S. hospitals.
Buruli ulcers, one of the 'neglected tropical diseases' left aside by big pharma and governments alike, are reasonably well treatable, also in poor regions. But then more attention has to be paid to early diagnosis and correct treatment. This means the rules of the World Health Organization urgently need to be changed. So say scientists of the Antwerp Institute of Tropical Medicine (ITM), based on ten years of research in Congo.
The 25th Anniversary Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 30-October 3, 2010, at the Gaylord Palms Hotel and Convention Center in Kissimee, FL. The symposium is sponsored by Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
WoundVision™, the healthcare industry pioneer in advanced wound detection technology, is introducing today a revolutionary predictive bedside thermographic imaging system. The WoundVision system brings knowledge bedside by acquiring, analyzing and applying essential patient data to inform healthcare providers in the development of effective treatment and care plans.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.